Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Controlled Clinical Trial
. 2007 Feb 6;49(5):554-61.
doi: 10.1016/j.jacc.2006.07.072. Epub 2007 Jan 22.

Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis

Luis M Moura  1 , Sandra F Ramos, José L Zamorano, Isabel M Barros, Luis F Azevedo, Francisco Rocha-Gonçalves, Nalini M Rajamannan
Affiliations
Controlled Clinical Trial

Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis

Luis M Moura et al. J Am Coll Cardiol. .

Abstract

Objectives: The objective of this study was to test the effect of a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor on the progression of moderate to severe aortic stenosis as measured by echocardiography.

Background: Recent retrospective studies support the hypothesis that statins slow the progression of aortic stenosis.

Methods: We performed an open-label, prospective study evaluating 121 consecutive patients with asymptomatic moderate to severe aortic stenosis (aortic valve area > or = 1.0 cm2; mean age 73.7 +/- 8.9 years; 57 men and 64 women), treated with and without rosuvastatin according to the National Cholesterol Education Program Adult Treatment Panel III guidelines. Echocardiographic, serum lipid, and inflammatory markers were measured at baseline and every 6 months for 18 months.

Results: Sixty-one patients (50.4%) with elevated LDL (159.7 +/- 33.4 mg/dl), aortic valve velocity (3.65 +/- 0.64 m/s), and aortic valve area (1.23 +/- 0.42 cm2) received rosuvastatin (20 mg/day), and 60 (49.6%) with a normal LDL (118.6 +/- 37.4 mg/dl), aortic valve velocity (3.62 +/- 0.61 m/s), and aortic valve area (1.20 +/- 0.35 cm2) received no statin. During a mean follow-up of 73 +/- 24 weeks, the change in aortic valve area in the control group was -0.10 +/- 0.09 cm2/year versus -0.05 +/- 0.12 cm2/year in the rosuvastatin group (p = 0.041). The increase in aortic valve velocity was 0.24 +/- 0.30 m/s/year in the control group and 0.04 +/- 0.38 m/s/year in the rosuvastatin group (p = 0.007). There was significant improvement in serum lipid and echocardiographic measures of aortic stenosis in the statin group.

Conclusions: Prospective treatment of aortic stenosis with rosuvastatin by targeting serum LDL slowed the hemodynamic progression of aortic stenosis. This is the first prospective study that shows a positive effect of statin therapy for this disease process. (Rosuvastatin Affecting Aortic Valve Endothelium; http://www.clinicaltrials.gov/ct/show/NCT00114491?order = 1; NCT0014491).

PubMed Disclaimer

Figures

Figure 1
Figure 1. Patient Flow Diagram
Flow chart of patient enrollment. pts = patients.
Figure 2
Figure 2. Progression of Aortic Valve Stenosis in Patients Treated With Rosuvastatin Therapy and Untreated Patients
(A) Aortic jet velocity in treated versus untreated patients. (B) Aortic mean gradient in treated versus untreated patients. (C) Aortic valve area in treated versus untreated patients.
Figure 3
Figure 3. Correlation of LDL Cholesterol With Echocardiographic Hemodynamic Measurements in Treated Patients
(A) Aortic jet velocity in treated patients. (B) Aortic mean gradient in treated patients. (C) Aortic valve area in treated patients. LDL = low-density lipoprotein.
See this image and copyright information in PMC

Comment in

References

    1. Lindroos M, Kupari M, Heikkila J, Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol. 1993;21:1220–5. - PubMed
    1. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111:920–5. - PubMed
    1. Ross J, Jr, Braunwald E. Aortic stenosis. Circulation. 1968;38(Suppl):61–7. - PubMed
    1. Bonow RO, Carabello B, de Leon AC, Jr, et al. Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease) Circulation. 1998;98:1949–84. - PubMed
    1. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630–4. - PubMed

Publication types

MeSH terms

Associated data